


Relationship of Acute ST-Elevation Myocardial Infarction with hs-CRP and Serum Iron Profile in Southern India: A Cross-sectional Study

MK MALTHESH¹, SIDDHARTH GOSAVI², SHASHANK SHASTRY³,
RAMYASRI RAJESH⁴, PRATYAKSH P VAISHNAV⁵, K MARUTHI⁶



ABSTRACT

Introduction: Cardiovascular diseases are a major cause of mortality. The role of Iron in oxidative myocardial damage remains controversial with multiple studies showing positive and negative correlations. Systemic inflammation is also an important factor in Myocardial Infarction (MI) with high sensitive C-Reactive Protein (hs-CRP) being an important marker.

Aim: To investigate the relationship of serum iron and hs-CRP in patients diagnosed with ST-segment Elevation Myocardial Infarction (STEMI) and its role as prognostic indicators.

Materials and Methods: A cross-sectional hospital-based study was conducted in which 45 patients were enrolled over a period of two months. Primary variables studied were STEMI and site of infarction as confirmed on echocardiography, hospital stay and patient outcome. Secondary variables were serum iron, hs-CRP, Total Iron Binding Capacity (TIBC), ferritin. Statistical analysis was done using IBM Statistical Package for the Social Sciences

(SPSS) software version 20. Mann-Whitney U test, Kruskal Wallis test, ANOVA and Spearman's rank correlation was used.

Results: Iron profile was significantly altered in the various types of MI. Serum iron values lower than 61 mg/dL had a sensitivity of 89% and high Negative Predictive Value (NPV) (95%) for the prediction of mortality in patients. It was seen that significantly lower Unbound Iron Binding Capacity (UIBC) values were seen in patients who died than the survivor group. Low Transferrin Saturation (TS), serum iron, TIBC were associated with a longer hospital stay. About 42 patients showed hs-CRP levels above 0.3 mg/L. High hs-CRP and ferritin values were associated with a prolonged hospital stay.

Conclusion: In patients with acute STEMI, serum iron and hs-CRP are shown to be important predictors of morbidity and mortality. Regular iron supplementation with a six monthly hs-CRP monitoring is recommended. Further research shows screening capability is needed.

Keywords: High sensitive C-reactive protein, Iron studies, Mortality

INTRODUCTION

Cardiovascular diseases continue to be a major cause of mortality in India contributing to 27% of proportional mortality as per statistics of 2016 [1]. Many risk factors for MI have been extensively researched upon such as smoking and tobacco use, Diabetes Mellitus (DM), Hypertension (HTN), dyslipidemia, obesity, psychosocial stress, elevated homocysteine levels and sedentary lifestyle [2]. Iron is one of the most important trace elements in the human body. It can accept and donate electrons by exchanging between ferrous and ferric forms. This generates reactive oxygen species through Fenton and Haber-Weiss reactions and is implicated to cause oxidative damage. It is in consideration of this, that Iron was implicated to increase risk of cardiovascular disease by causing bio-membrane damage [3]. Studies by Menke A et al., and Rajapurkar MM et al., have shown that excess body iron stores are associated with higher incidence or worse prognosis of cardiovascular diseases [4,5]. However, the role of iron is still controversial. Kervinen H et al., studied the association between serum iron and chronic heart disease in a nested case-control study. The subjects with low iron were at an increased risk (OR=9.8; 95% CI: 3.9-24.4). The probability of increased coronary events correlated with a decrease in serum iron levels [6].

In a prospective nested case-referent study, Ekblom K et al., the authors found an inverse risk association for MI in the highest quartiles of iron (OR=0.68; 95% CI: 0.48-0.96) and TS (OR=0.62; 95% CI: 0.42-0.89) in men. The researchers hence inferred that iron levels in the upper normal range seemed to be associated with a lower risk for first MI [7]. Inflammation has been identified as

an important factor in Acute MI. It is caused by pro-inflammatory cytokines, which are released from the inflamed tissue by inflammatory and parenchymal cells. Hs-CRP is the classical acute phase reactant protein, the serum level of which has long been known to increase in Acute Myocardial Infarction (AMI) [8,9]. Hs-CRP is an attractive biomarker and has opsonising properties. It pushes the monocytes into the atheroma, suppresses the basal and induce nitric oxide release leading to endothelial dysfunction [9]. In a study by Kervinen H et al., it was concluded that patients with raised hs-CRP were at an increased risk for cardiovascular disease [6].

With the given background, we hope to gain a better understanding about the role of iron and hs-CRP in predicting patient outcomes in MI and hence, the present study was conducted to study the association of deranged iron profile and raised hs-CRP in patients diagnosed with STEMI.

MATERIALS AND METHODS

This was a cross-sectional hospital-based study of in-patients admitted in the Department of General Medicine and Cardiology at Chigateri General Hospital and Bapuji Hospital-JJM Medical College, Davanagere, Karnataka, India. The study duration was of two months (1st April to 31st May 2020). All the patients were residents of Davanagere district Karnataka, belonging to lower socio-economic strata [10].

The study was commenced after the institutional ethical clearance (Number-87-2020). Informed written consent was taken from the patients if they were stable enough for the same. In cases, where patients were critically ill and unable to read and sign the form, the patient's attenders were asked to sign on their behalf.

The inclusion criteria were defined as patients with:

- 1) Newly diagnosed acute STEMI in ages between 18 to 85 years, confirmed by echocardiography.

The exclusion criteria were patients with:

- 1) Old ischemic heart disease,
- 2) NSTEMI
- 3) Malignancies,
- 4) Chronic Kidney Disease (CKD),
- 5) Patients with acute febrile illness (deranges Hs-CRP)

About 93 patients were screened over the two months and 48 were excluded (CKD-11, malignancy-2, NSTEMI-18, Acute febrile illness-8, Not given consent-9) and 45 patients were finally selected to participate in the study. Primary variables studied were STEMI and site of infarction as confirmed on echocardiography, hospital stay and patient outcome. Secondary variables were serum iron, hs-CRP, TIBC and ferritin. Serum iron profile including Serum Iron, Serum Ferritin, UIBC, TIBC and TS. Hs-CRP was measured by a method called latex enhanced immunoturbidimetric assay (Normal-0-0.5 mg/dL). Complete Blood Count (CBC) was done by the haematology analyser which is a laser-based measurement. The iron studies were analysed via a dry chemistry method. This is the method used in Bapuji Hospital JJMMC, Davanagere, Karnataka, India. Information was provided by Bapuji Hospital Central Laboratory. CBC, hs-CRP and iron studies were performed on all the 45 patients. Patients were observed during their hospital stay till they survived or succumbed to illness. Site of MI and duration of hospital stay were also noted. History of diabetes, HTN, smoking and alcohol were taken into consideration as they are possible effective modifiers. Patients were followed-up during hospital stay. Possible predictors to be investigated were serum iron levels, TIBC, TS, ferritin, and hs-CRP.

STATISTICAL ANALYSIS

Statistical analysis was done using IBM SPSS software. Results are presented as Mean±SD values for continuous variables and frequency as number and percentages. Since, the measurements were found to be moderately skewed, non-parametric methods were used for analysis. Mann-Whitney U test was used to compare between survivors and deceased groups. Kruskal-Wallis ANOVA was used for multiple groups (sites of MI) simultaneous comparisons. Categorical data were analysed by Chi-square test. Diagnostic validity tests were performed to predict the prognosis. A confidence interval of 95% was chosen. Correlation was measured by Spearman's rank correlation coefficient. A p-value of 0.05 or less was considered for statistical significance.

RESULTS

About 45 patients participated in the study (27 males and 18 females). About nine patients succumbed to MI and 36 survived. There were

15 patients with Anterior wall STEMI, nine patients with Anterolateral STEMI, 15 with Inferior wall STEMI, six with Inferolateral wall STEMI. About nine patients had DM, six patients had HTN and six patients had both DM and HTN [Table/Fig-1].

Descriptive information on study subjects				Died	Survived
No. of cases		45		9	36
Age (Years)	Mean±SD	63.4±11.8			
	Range	43-83			
		No.	%		
Gender	Male	27	60.0	2	25
	Female	18	40.0	7	11
Diagnosis	1. Anterior wall STEMI	15	33.3	3	12
	2. Anterolateral wall STEMI	9	20	2	7
	3. Inferior wall STEMI	15	33.3	1	14
	4. Inferolateral STEMI	6	13.3	3	3
	Total	45	100	9	36
Diabetes Mellitus (DM) only		9	20.0	1	8
Hypertension (HTN) only		6	13.3	0	6
Both DM and HTN		6	13.3	2	4
Neither DM nor HTN		24	53.3	6	18
Only smokers		15	33.3	4	11
Only alcoholics		19	42.2	3	16
Both smoker and alcoholic		11	24.4	2	9
Hospital stay (days)	Mean±SD	12.6±3.1		13.67±2.4	12.6±3.3
	Range	7-18 days		9-18 days	7-18 days

[Table/Fig-1]: Descriptive information on study subjects.

About 18 out of 45 (40%) {12 Male and 6 Female} had Serum Iron values below 40 µg/dL, 9 out of 45 (20%) had Serum Iron values between 40-67 µg/dL, and the rest had Iron values above 67 µg/dL. (Normal values=Males-49-181 µg/dL, Females-37-170 µg/dL). Mean serum iron values were normal for anterior wall STEMI and inferior wall STEMI. However, in anterolateral wall STEMI and inferolateral wall STEMI, mean serum iron values were reduced. A p-value of 0.001 was obtained [Table/Fig-2].

It was seen that Serum Iron values lower than 61 mg/dL (cut-off chosen since it was the median value across all study subjects. Due to the high range between highest and lowest values, it was statistically more apt to select the numerical median as the cut-off) had a sensitivity of 89% and specificity of 56% with high NPV of 95% for prediction of mortality in patients [Table/Fig-3].

Patients with low serum iron showed prolonged hospital stay ($r=-0.60$, $p=0.01$) [Table/Fig-4]. About 27 out of 45 had TIBC lower than 260 µg/dL. Other 18 had normal values (Normal values=Males-261-462 µg/dL, Females-260-497 µg/dL). Anterolateral wall STEMI

Diagnosis		Iron (in µg/dL)	TIBC (in µg/dL)	UIBC (in µg/dL)	TS (in %)	Ferritin (in µg/dL)	Hs-CRP (in mg/L)	Red cell distribution width (in %)
		Mean	Mean	Mean	Mean	Mean	Mean	Mean
1. Anterior wall STEMI		62.9±25.5	341.5±88.2	297.8±106.8	17.5±5.7	102.6±58.4	2.99±3.46	15.3±2.0
2. Anterolateral wall STEMI		19.7±4.3	228.1±26.8	208.0±23.0	8.5±1.2	269.4±163.9	7.47±2.72	17.4±4.8
3. Inferior wall STEMI		72.1±29.0	266.4±36.1	250.6±60.4	22.5±10.9	137.6±79.2	2.88±2.11	16.6±3.3
4. Inferolateral STEMI		40.3±27.8	292.3±84.8	255.5±60.8	12.2±5.8	76.5±45.5	11.14±11.78	15.5±4.8
Overall		54.3±31.1	287.2±75.5	258.5±79.9	16.7±9.0	144.2±112.4	4.94±5.62	16.2±3.5
Kruskal-Wallis's ANOVA	χ ²	16.89	10.14	5.28	13.86	13.53	9.00	2.46
	p	0.001*	0.02*	0.15, ns	0.003*	0.004*	0.03*	0.48, ns

[Table/Fig-2]: Diagnosis-wise comparison of different parameters.

TIBC: Total iron-binding capacity; UIBC: Unbound iron binding capacity; TS: Transferrin saturation; hs-CRP: High sensitive C-reactive protein; STEMI-ST: Segment elevation myocardial infarction; ns- non significant; p<0.05 - significant

Iron	Outcome		Total
	Died	Survived	
<61.0 mg/dL	8 (90.0)	16 (44.4)	24 (53.3)
>61.0 mg/dL	1 (10.0)	20 (55.6)	21 (46.7)
Total	9 (100)	36 (100)	45 (100)

[Table/Fig-3]: Diagnostic value of Iron in the prognosis of MI (cut-off value of Iron=61.0). $\chi^2=5.71$, $p=0.024$; $p<0.05$ - significant

cases showed low mean TIBC with a significant p-value of 0.02 [Table/Fig-2]. Patients with lower TIBC had prolonged hospital stay ($r=-0.41$, $p=0.01$) [Table/Fig-4].

Parameter	Spearman's R coefficient	p-value	Significance
Hs-CRP	0.51	0.0001	Significant
UIBC	-0.19	0.22	Not significant
TS	-0.64	0.0001	Significant
Iron	-0.60	0.01	Significant
Ferritin	0.38	0.01	Significant
TIBC	-0.41	0.01	Significant

[Table/Fig-4]: Correlation between serum iron profile and hs-CRP and duration of hospital stay.

Spearman Rank r correlation, $p<0.05$ - significant

TIBC: Total iron-binding capacity; UIBC: Unbound iron binding capacity; TS: Transferrin saturation; hs-CRP: High sensitive C-reactive protein

About 18 out of 45 patients had low TS below 14%. Other patients had normal TS (Normal values=15-50%) Mean TS was low in inferolateral and anterolateral STEMI with a significant p-value of 0.003 [Table/Fig-2]. Patients with low TS had prolonged hospital stay ($r=-0.64$, $p=0.0001$) [Table/Fig-4]. About 15 out of 45 had serum ferritin values below 110 $\mu\text{g/dL}$, 24 had serum ferritin values between 111-219 $\mu\text{g/dL}$, six had serum ferritin values more than 220 $\mu\text{g/dL}$ (Normal=Males-22-274, Females-10-204). Mean Ferritin was high only in anterolateral wall STEMI with significant p-value of 0.004 [Table/Fig-2]. Higher ferritin values weakly correlated to longer hospital stay ($r=0.38$, $p=0.01$) [Table/Fig-4]. The most striking finding was seen with hs-CRP. About 42 out of 45 patients showed hs-CRP levels above 0.3 mg/L. (Normal values- <0.1 mg/L, Average cardiac risk- 0.1-0.3, High cardiac risk- >0.3 mg/L). HS-CRP was found to be high in all types of MI with a p-value of 0.03 [Table/Fig-2].

Hs-CRP was seen to have a sensitivity of 100%, a specificity of 42% and NPV of 100% in predicting mortality (cut-off chosen since it was the median value across all study subjects. Due to the high range between highest and lowest values, it was statistically more apt to select the numerical median as the cut-off) [Table/Fig-5]. Only 6 out of 45 patients had abnormal UIBC values. But it was seen that significantly lower UIBC values were seen in patients who died than the survivor group ($p=0.04$) [Table/Fig-6]. UIBC showed no significant correlation with the duration of hospital stay [Table/Fig-4].

Hs-CRP (in mg/L)	Outcome		Total
	Died	Survived	
>2.0	9 (100.0)	21 (58.3)	30 (66.7)
<2.0	0 (0.0)	15 (41.7)	15 (33.3)
Total	9 (100)	36 (100)	45 (100)

[Table/Fig-5]: Diagnostic value of hs-CRP in the prognosis of MI (Cut-off the value of Hs-CRP=2.0).

$\chi^2=5.63$; $p=0.02$; $p<0.05$ - significant

Raised hs-CRP was seen in the deceased as compared to the survivor group [Table/Fig-6]. Raised hs-CRP was also associated with prolonged hospital stay ($r=0.51$, $p=0.0001$) [Table/Fig-4].

The remarkable finding of the study is that none of the patients enrolled in the study was anaemic. The investigations were sent after the onset of the MI and no fall in Haemoglobin was seen.


It was seen that lower values of iron were strongly associated with higher values of Hs-CRP [Table/Fig-7] ($r=-0.68$, $p=0.0001$).

	Died (9)	Survived (36)	p-value
	Mean \pm SD	Mean \pm SD	
Iron (in $\mu\text{g/dL}$)	40.0 \pm 28.8	57.9 \pm 31.1	0.07, ns
TIBC (in $\mu\text{g/dL}$)	240.4 \pm 19.7	298.9 \pm 79.9.0	0.11, ns
UIBC (in $\mu\text{g/dL}$)	213.3\pm36.9	269.8\pm84.0	0.04*, S
TS (in %)	15.3 \pm 9.4	17.0 \pm 9.0	0.50, ns
Ferritin (in $\mu\text{g/dL}$)	214.2 \pm 157.3	126.6 \pm 93.0	0.15, ns
Hs-CRP (in mg/L)	10.9\pm8.92	3.46\pm3.19	0.008*, S
RDW (in %)	15.9 \pm 3.1	16.2 \pm 3.6	0.83, ns

[Table/Fig-6]: Initial levels (at admission) of Iron, Ferritin, Hs-CRP, TIBC, UIBC, TS, RDW and other variables relating to outcome.

Mann-Whitney U test is done, $p<0.05$ - significant

TIBC: Total iron-binding capacity; UIBC: Unbound iron binding capacity; TS: Transferrin saturation; hs-CRP: High sensitive C-reactive protein; RDW: Red cell distribution width



[Table/Fig-7]: Depicting relationship between iron values and hs-CRP ($r=-0.68$, $p=0.0001$).

DISCUSSION

The protective action of iron has not been completely understood. The well-known role of iron in free-radical-mediated injury is decreased in ischemic myocardial events. Iron depletion protects myocardium by directly inhibiting atherogenesis. Iron depletion can defend against ischemic events, even in patients with considerable atherosclerotic disease [11]. The novel findings put forward that iron could have a clinically more vital function in ischemic events than in initiating or promoting vascular structural lesions. Increased events may occur without an increase in atherosclerotic lesions [12]. Iron deficiency is a common co-morbidity associated with poor prognosis in cardiac conditions. In a study, by Duarte T et al., patients with serum iron values of less than 40 $\mu\text{g/dL}$ had a higher incidence of adverse cardiovascular events [12]. About 18 out of 45 patients had serum iron values less than 40 $\mu\text{g/dL}$ in this study, out of which five patients succumbed to illness with an average hospital stay of 15.1 days as compared to the general average of 12.6 days. This study correlates with the study done by Griffith JD et al., in which it is suggestive that the presence of MI alters the behaviour of plasma iron and is reduced at the time of admission [13]. This study also suggests that the iron remains reduced up till day seven of admission. In this study, however, due to financial constraints of the patient, we could only perform iron studies at admission. Blockage of haemoglobin from the reticuloendothelial system occurs in acute MI with a longer half-life of seven days. Another probable reason could be lactoferrin release leading to leukocyte agranulocytosis. Reduction in TIBC is directly proportional to a reduction in plasma transferrin. A shift of plasma iron into the hepatocyte reduces hepatic transferrin synthesis. The acute changes of iron, transferrin and ferritin lead to a temporary arrest in erythropoiesis leading to a fall in haemoglobin. However, none of the patients had a fall in haemoglobin [13].

TIBC is an independent important negative risk factor for MI. This was derived in a study by Magnusson MK et al., [14]. In the present study, 27 out of 45 patients (60% of patients) had TIBC lower than 260 $\mu\text{g/dL}$, out of which 9 patients died. Anterolateral wall STEMI cases showed lower mean TIBC with a significant p-value of 0.02 [Table/Fig-2]. Atherosclerotic plaques formation is influenced by the integrity of the fibrous cap due to inflammatory mechanisms.

Hs-CRP is an attractive biomarker and has opsonising properties. It pushes the monocytes into the atheroma, suppresses the basal and induced nitric oxide release leading to endothelial dysfunction [9]. Hs-CRP also is an important predictor of type 2 DM. The Indian population is more prone to coronary artery diseases, DM and metabolic syndrome, so, hs-CRP values are likely higher in our country [9]. The striking feature of this study was that mean Hs-CRP was found to be high in all types of MI with a p-value of 0.03. About 42 out of 45 patients showed Hs-CRP levels above 0.3 mg/L. (Normal values- <0.1 mg/L, Average cardiac risk- 0.1-0.3, High cardiac risk- >0.3 mg/L). This study also shows a positive correlation between hs-CRP values with the duration of hospital stay and increased incidence of death. This agrees with a study done by Soinio M et al., which showed that in patients with DM, high hs-CRP was an independent risk factor to predict mortality from coronary heart disease [15]. Oxidative free radicals have a major role in CAD. There is increased peroxidation of LDL, leading to increased uptake by macrophages thereby leading to increased foam cell formation and atherosclerosis. Iron is an especially important constituent and free iron produces free radicals; therefore, it is involved in lipid peroxidation and atherosclerosis leading to Acute MI [15]. In a study by Badiger RH et al., it was observed that serum ferritin levels were higher in patients with acute MI [8]. Mean ferritin was high only in anterolateral wall STEMI in present study. Iron induced lipid peroxidation has been considered as the age-old mechanism. Since inflammation is implied in MI, we expected a significant rise in serum ferritin as it an acute phase reactant. A cohort study with long term follow-up and repeat iron profile and serial hs-CRP monitoring can help establish their role in heart disease.

Limitation(s)

Limitation of the study would be small sample size, lack of follow-up until the next cardiac event and due to financial constraints, no repeat investigations could be performed on patients.

CONCLUSION(S)

Physicians must be aware of the implications of iron metabolism in the pathogenesis of acute STEMI. Regular iron supplementation with a six monthly hs-CRP monitoring is recommended and can be counted as crucial prognostic tools in acute MI. In patients admitted with acute MI, iron profile and hs-CRP are shown to be

important predictors of morbidity and mortality. Physicians must note that these fairly basic and inexpensive measures can go a long way in improving patient care and contribute to preventing morbidity and mortality.

REFERENCES

- [1] Who.int [Internet]. Rome. Strengthening nutrition action: A resource guide for countries based on the policy recommendations of the Second International Conference on Nutrition (ICN2). Inc; c2020 [updated 2018 September 24; cited 2020 Aug 30]. Available from: <https://www.who.int/publications/item/9789241550253>.
- [2] Emedicine.Medscape.com [Internet]. New York. Myocardial infarction. Inc; c1994-2020 [updated 2019 May 7; cited 2020 Aug 30]. Available from: <https://emedicine.medscape.com/article/155919-overview>.
- [3] Muñoz-Bravo C, Gutiérrez-Bedmar M, Gómez-Aracena J, García-Rodríguez A, Navajas JF-C. Iron: Protector or risk factor for cardiovascular disease? Still controversial. *Nutrients*. 2013;5(7):2384-404.
- [4] Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord* [Internet]. 2009;9(1). Available from: <http://dx.doi.org/10.1186/1471-2261-9-34>.
- [5] Rajapurkar MM, Lele SS, Malavade TS, Kansara MR, Hegde UN, Gohel KD, et al. Serum catalytic Iron: A novel biomarker for coronary artery disease in patients on maintenance hemodialysis. *Indian J Nephrol*. 2013;23(5):332-37.
- [6] Kervinen H, Tenkanen L, Palosuo T, Roivainen M, Manninen V, Mänttari M. Serum iron, infection and inflammation; effects on coronary risk. *Scand Cardiovasc J*. 2004;38(6):345-48.
- [7] Ekblom K, Marklund SL, Jansson JH, Hallmans G, Weinehall L, Hulthén J. Iron stores and HFE genotypes are not related to increased risk of first-time myocardial infarction: A prospective nested case-referent study. *Int J Cardiol*. 2011;150(2):169-72.
- [8] Badiger RH, Dinesha V, Hosalli A, Ashwin SP. Hs-C-reactive protein as an indicator for prognosis in acute myocardial infarction. *J Sci Soc*. 2014;41(2):118.
- [9] Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. *Indian J Med Res*. 2015;142(3):261-68.
- [10] Mahmood SE. Prasad's socioeconomic scale updated for 2019 [Internet]. Njcmindia.org. 1970 [cited 2020 Aug 30]. Available from: <http://www.njcmindia.org/home/download/1385>.
- [11] Sullivan JL. Iron and the genetics of cardiovascular disease. *Circulation*. 1999;100(12):1260-63.
- [12] Duarte T, Gonçalves S, Sá C, Rodrigues R, Marinheiro R, Fonseca M, et al. Prognostic impact of iron metabolism changes in patients with acute coronary syndrome. *Arq Bras Cardiol*. 2018;111(2):144-50.
- [13] Griffiths JD, Campbell LJ, Woodruff IW, Cruickshank D, Matthews JP, Hunt D, et al. Acute changes in iron metabolism following myocardial infarction. *Am J Clin Pathol*. 1985;84(5):649-54.
- [14] Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgerisson G. Low iron-binding capacity as a risk factor for myocardial infarction. *Circulation*. 1994;89(1):102-08.
- [15] Soinio M, Marniemi J, Laakso M, Lehto S, Rönkämaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. *Diabetes Care*. 2006;29(2):329-33.

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Cardiology, JJM Medical College, Davanagere, Karnataka, India.
2. Postgraduate Resident, Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.
3. Intern Medical Officer, Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.
4. Intern Medical Officer, Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.
5. Intern Medical Officer, Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.
6. Intern Medical Officer, Department of General Medicine, JJM Medical College, Davanagere, Karnataka, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Siddharth Gosavi,
Department of General Medicine, JJM Medical College, Dental College Road,
Davanagere-577004, Karnataka, India.
E-mail: ramshyamsid@gmail.com

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Jul 09, 2020
- Manual Googling: Sep 12, 2020
- iThenticate Software: Oct 16, 2020 (5%)

ETYMOLOGY: Author Origin

Date of Submission: Jul 08, 2020
Date of Peer Review: Jul 28, 2020
Date of Acceptance: Sep 12, 2020
Date of Publishing: Nov 01, 2020